The COVID-19 Treatment Guidelines were developed to provide clinicians with guidance on caring for
patients with COVID-19. Because clinical information about the optimal management of COVID-19
is evolving quickly, these Guidelines are updated frequently to reflect newly published data and other
authorita...
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Commercial arrangement
There is a simple discount patient access scheme for maribavir. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisat...
Barbosa, Alexandre Naime;
Chebabo, Alberto;
Pérez, Clevy;
Cunha, Clóvis Arns;
Luna, David de;
Nunes, Estevão Portela;
Zambrano, Gabriela;
Ferreira, Juliana Carvalho;
Croda, Júlio;
Falavigna, Maicon;
Silva, Monica Maria Gomes da;
Cimerman, Sergio;
Parahiba, Suena Medeiros;
Tanni, Suzana;
Bernardo, Wanderley Marques;
Rodriguez-Morales, Alfonso J.
Since the beginning of the COVID-19 pandemic, therapeutic options for treating COVID-19 have been investigated at different stages of clinical manifestations. Considering the particular impact of COVID-19 in the Americas, this document aims to present recommendations for the pharmacological treatment of ...
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, an...
Inhibidores de las Cinasas Janus/uso terapéutico,
COVID-19/tratamiento farmacológico,
Antivirales/uso terapéutico,
Ivermectina/uso terapéutico,
Hidroxicloroquina/uso terapéutico,
Plasma/inmunología,
Fluvoxamina/uso terapéutico,
Colchicina/uso terapéutico,
Inmunización Pasiva,
Receptores de Interleucina-6/uso terapéutico,
Lopinavir/uso terapéutico,
Corticoesteroides/uso terapéutico
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use ...
COVID-19/tratamiento farmacológico,
Corticoesteroides/uso terapéutico,
Antivirales/uso terapéutico,
COVID-19/complicaciones,
Embolia Pulmonar/complicaciones,
Pulmón/patología,
Anticoagulantes/uso terapéutico,
Dabigatrán/uso terapéutico,
Heparina/uso terapéutico,
4-Hidroxicumarinas/uso terapéutico,
Aspirina/uso terapéutico
El tratamiento oportuno de personas con COVID-19 busca minimizar el número de
complicaciones y muertes por esta enfermedad. Por ello, el Seguro Social de Salud del Perú
(EsSalud) priorizó la realización de la presente guía de práctica clínica (GPC) con la finalidad de
establecer recomendaciones ba...
According to WHO data, 71 million people worldwide were infected with hepatitis C virus (HCV) in 2015, corresponding to a prevalence of 1%. 399,000 people die annually from complications of liver cirrhosis, including hepatocellular carcinoma.
This KDP answers the following clinical questions:
Diagnos...
El tratamiento oportuno de personas con COVID-19 busca minimizar el número de
complicaciones y muertes por esta enfermedad. Por ello, el Seguro Social de Salud del Perú
(EsSalud) priorizó la realización de la presente guía de práctica clínica (GPC) con la finalidad de
establecer recomendaciones ba...
The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new...
The Practice Guidelines Committee of the American Society for Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update its 2009 compendium-style infectious diseases guidelines for the care of hematopoietic cell transplant (HCT) recipients. A n...
